Brazil: firms to define priority of multiple product applications
This article was originally published in Clinica
In line with its promise to shorten healthcare product approval times, Brazilian regulatory agency Anvisa has said it will allow companies with multiple applications pending to specify the order of priority in which their products should be reviewed.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.